Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Frequently asked questions
What sector does Sera Prognostics Inc (SERA) operate in?
Sera Prognostics Inc belongs to the Healthcare sector and operates in the Medical Devices industry.
What is Sera Prognostics Inc (SERA) current stock price?
As of the latest data, Sera Prognostics Inc stock price is $2.04, with a previous close of $1.93. Sera Prognostics Inc gained $0.11 in the last trading session, representing a 5.7% increase.
What is Sera Prognostics Inc (SERA) current market capitalization?
Sera Prognostics Inc market cap is approximately 78.50 million.
What is Sera Prognostics Inc (SERA) Earnings Per Share (EPS)?
The trailing EPS is -$0.67, and the forward EPS is -$0.58.
What is Sera Prognostics Inc (SERA) EBITDA?
Sera Prognostics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -10.00 million.
Does Sera Prognostics Inc (SERA) pay dividends?
No. Sera Prognostics Inc does not pay a dividend.
How did Sera Prognostics Inc (SERA) perform in its most recent earnings report?
In the last report (June 30, 2026), Sera Prognostics Inc posted an EPS surprise of -28.57% and a revenue surprise of -40%.
What is Sera Prognostics Inc (SERA) beta (volatility) score?
Sera Prognostics Inc has a beta of 0.984, meaning its volatility is roughly in line with the market.
